But we think the key area is, we think there's a great opportunity to bring Copper-67 bisPSMA even into first-line therapy, even if it's a single dose, in combination with something like an ARPI. We think the ARPI radiopharm combination is fantastic. We think we are best suited for that. We like that ARPIs increase the expression of PSMA. We think that combination therapy actually probably presents the best opportunity for potential curative outcomes in much earlier stage disease.If you're upregulating the receptor, if you're hitting it as hard as you can with a Copper-67 bisPSMA, I think that represents the best chance. And if you're getting near no side effects, or reducing the side effects of ARPIs, that's a great outcome for the patients. Now, that is a fantastic, I think that's the jewel in the crown. That's what we're aiming for as a company, and we think it's a great opportunity for us, and we'll be looking further into that.
CU6 Price at posting:
$6.50 Sentiment: Hold Disclosure: Held
